CHINARES PHARMA (03320): CHINARES PHARMA reported a net profit attributable to the parent company of 930 million yuan in the first half of the year, an increase of 3.45% compared to the same period last year.
China Resources Pharmaceutical (03320) announced that its non-wholly owned subsidiary, China Resources Pharmaceutical Commercial Group Co., Ltd. (China Resources Pharmaceutical Commercial), achieved operating revenue of RMB 111.562 billion for the six months ending June 30, 2026, an increase of 2.87% year-on-year; net profit attributable to the owners of the parent company was RMB 930 million, an increase of 3.45% year-on-year.
CHINARES PHARMA (03320) announced that the company's non-wholly-owned subsidiary, CHINARES PHARMA Commercial Group Co., Ltd. (CHINARES PHARMA Commercial), achieved operating revenue of RMB 111.562 billion for the six months ending June 30, 2026, an increase of 2.87% year-on-year; the net profit attributable to owners of the parent company was RMB 930 million, an increase of 3.45% year-on-year.
Related Articles
ZYY (08223) released its interim results, with a profit attributable to shareholders of 5.771 million yuan, a decrease of 14.57% compared to the same period last year.
E-HOUSE ENT (02048) released its interim results, with a profit attributable to shareholders of 45.245 million yuan, achieving a turnaround from loss to profit compared to the same period last year.
MAXNERVA TECH (01037) released its mid-term performance report, with a net profit of 8.853 million yuan, turning losses into profits year-on-year.
ZYY (08223) released its interim results, with a profit attributable to shareholders of 5.771 million yuan, a decrease of 14.57% compared to the same period last year.
E-HOUSE ENT (02048) released its interim results, with a profit attributable to shareholders of 45.245 million yuan, achieving a turnaround from loss to profit compared to the same period last year.
MAXNERVA TECH (01037) released its mid-term performance report, with a net profit of 8.853 million yuan, turning losses into profits year-on-year.
RECOMMEND
